Patient-Reported Outcomes (PROs) From DESTINY-Breast04, a Randomized Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) vs Treatment of Physician's Choice (TPC) in Patients (pts) With HER2-Low Metastatic Breast Cancer (MBC)
Trastuzumab Deruxtecan
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Patient-Reported Outcomes (PROs) From DESTINY-Breast04, a Randomized Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) vs Treatment of Physician's Choice (TPC) in Patients (pts) With HER2-Low Metastatic Breast Cancer (MBC) ### Output: Trastuzumab Deruxtecan